BeOne director sells 38K ADS after option exercise
BeOne Medicines director Wang Xiaodong exercised options and sold ADSs under a Rule 10b5-1 plan while retaining a large ordinary share position.
Rhea-AI Filing Summary
BeOne Medicines Ltd. (ONC) director and Scientific Advisory Board chair Wang Xiaodong reported multiple equity transactions on September 8, 2026. He exercised options covering 403,351 Ordinary Shares at an exercise price of $2.84 per share, leaving options on 1,210,079 Ordinary Shares outstanding. On the same date, he acquired 31,027 American Depositary Shares (ADS) (each ADS representing 13 Ordinary Shares) through an exercise or conversion and sold a total of 38,287 ADS in a series of open-market transactions at weighted-average prices in the mid-$300s per ADS, executed under a Rule 10b5-1 trading plan adopted on June 9, 2026. Following these transactions, he directly held 4,588,113 Ordinary Shares and also had indirect interests through family-related entities and a family trust, for which he disclaims beneficial ownership.
Positive
- None.
Negative
- None.
Insights
Analyzing...
Insider Trade Summary 10b5-1
Exercise and sale activity reported; no spread calculated
Exercise and Sale
14 txns
Insider
Wang Xiaodong
Role
Director
Sold
38,287 shs ($13.37M)
Approx. gross sale proceeds
$13.37M
Approx. exercise cost
$1.15M
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Share Option (Right to Buy) F14, F15 | 403,351 | $0.00 | $0.00 |
| Sale | American Depositary Shares F4, F5, F6 | 1,181 | $345.383 | $408K |
| Sale | American Depositary Shares F4, F5, F7 | 2,841 | $346.1575 | $983K |
| Sale | American Depositary Shares F4, F5, F8 | 1,517 | $347.3915 | $527K |
| Sale | American Depositary Shares F4, F5, F9 | 1,721 | $348.0126 | $599K |
| Exercise | American Depositary Shares F4 | 31,027 | $36.90 | $1.14M |
| Sale | American Depositary Shares F4, F5, F10 | 7,492 | $348.3146 | $2.61M |
| Sale | American Depositary Shares F4, F5, F11 | 10,688 | $349.2834 | $3.73M |
| Sale | American Depositary Shares F4, F5, F12 | 6,569 | $350.2741 | $2.30M |
| Sale | American Depositary Shares F4, F5, F13 | 6,278 | $351.2542 | $2.21M |
| holding | Ordinary Shares | -- | -- | -- |
| holding | Ordinary Shares F1 | -- | -- | -- |
| holding | Ordinary Shares F2 | -- | -- | -- |
| holding | Ordinary Shares F3 | -- | -- | -- |
Holdings After Transaction:
Share Option (Right to Buy) — 1,210,079 contracts (Direct);
American Depositary Shares — 0 shares (Direct);
Ordinary Shares — 4,588,113 shares (Direct);
Ordinary Shares — 4,978,213 shares (Indirect, See Footnote)
Footnotes (15)
- F1. These securities are held by a family trust, the beneficiaries of which are the Reporting Person's family members, for which the Reporting Person disclaims beneficial ownership.
- F2. These securities are held by Wang Investment LLC, of which 99% of the limited liability company interests are owned by two grantor retained annuity trusts, of which the Reporting Person's wife is a trustee, for which the Reporting Person disclaims beneficial ownership.
- F3. These securities are held by the spouse of the Reporting Person.
- F4. Each American Depositary Share represents 13 Ordinary Shares.
- F5. The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 9, 2026.
- F6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $344.71 to $345.66, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
- F7. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $345.71 to $346.70, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
- F8. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $346.79 to $347.78, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
- F9. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $347.80 to $348.07, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
- F10. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $348.07 to $348.79, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
- F11. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $348.80 to $349.74, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
- F12. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $349.81 to $350.80, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
- F13. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $350.82 to $351.74, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
- F14. The number of securities underlying each option and the exercise price therefor are represented in ordinary shares.
- F15. These securities vest over a four-year period as follows: 25% on July 13, 2017, and the remaining in 36 successive equal monthly installments, subject to continued service. All unvested shares subject to this option are subject to accelerated vesting upon certain termination events.
Key Figures
Options exercised: 403,351 Ordinary Shares
Option exercise price: $2.84 per Ordinary Share
ADS acquired via exercise/conversion: 31,027 ADS
+5 more
8 metrics
Options exercised
403,351 Ordinary Shares
Share options exercised by Wang Xiaodong on September 8, 2026
Option exercise price
$2.84 per Ordinary Share
Exercise price for 403,351 Ordinary Shares underlying options
ADS acquired via exercise/conversion
31,027 ADS
American Depositary Shares acquired on September 8, 2026
ADS sold
38,287 ADS
Total American Depositary Shares sold across reported transactions
ADS-to-Ordinary Share ratio
1 ADS : 13 Ordinary Shares
Ratio stated for BeOne Medicines American Depositary Shares
Direct Ordinary Shares after transactions
4,588,113 Ordinary Shares
Direct holdings of Wang Xiaodong following reported transactions
Options outstanding after exercise
1,210,079 Ordinary Shares
Ordinary Shares underlying options remaining after the reported exercise
ADS exercise/conversion price
$36.90 per ADS
Reported price for acquisition of 31,027 American Depositary Shares
Key Terms
Rule 10b5-1 trading plan, American Depositary Shares, grantor retained annuity trusts, weighted average price, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"The sale was effected pursuant to a Rule 10b5-1 trading plan adopted"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
grantor retained annuity trusts financial
"owned by two grantor retained annuity trusts, of which the Reporting"
A grantor retained annuity trust (GRAT) is an estate-planning tool where an owner transfers assets into a trust and receives fixed payments back for a set number of years; any remaining assets after that period pass to designated beneficiaries. For investors it matters because it can move future investment growth to heirs while potentially reducing gift and estate taxes — like putting a rising asset in a timed box that pays you first and gives the remaining upside to others.
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
beneficial ownership regulatory
"for which the Reporting Person disclaims beneficial ownership."
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
FAQ
What insider transactions did ONC director Wang Xiaodong report on September 8, 2026?
Wang Xiaodong reported exercising options for 403,351 Ordinary Shares at $2.84 per share, acquiring 31,027 ADS and selling a total of 38,287 ADS in multiple open-market transactions at weighted-average prices in the mid-$300s per ADS.
How many BeOne Medicines (ONC) options did Wang Xiaodong exercise and what was the strike price?
He exercised options covering 403,351 Ordinary Shares of BeOne Medicines at an exercise price of $2.84 per share. These options were part of a grant that vests over four years, with unvested portions subject to accelerated vesting upon certain termination events.
How many BeOne Medicines options does Wang Xiaodong still hold after the Form 4 transactions?
Following the option exercise reported, he continued to hold options on 1,210,079 Ordinary Shares. These options relate to grants that vest over time and may be subject to accelerated vesting upon certain termination events as described in the footnotes.
AI-generated analysis. How Rhea-AI works. Not financial advice.
